RevMab

anti-WT1 (human), Rabbit Monoclonal (RM516)

CHF 468.00
In stock
REV-31-1408-00-R100100 µlCHF 468.00
More Information
Product Details
Synonyms Wilms Tumor Protein; WT33
Product Type Recombinant Antibody
Properties
Clone RM516
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to residues near the N-terminus of human WT1.
Application

Immunohistochemistry (IHC): 1:100-1:200
Western Blot (WB): 1:500-1:1000

Crossreactivity Human
Specificity

This antibody reacts to human WT1 (Wilms tumor protein).

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P19544
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

WT1, a sporadic and familial pediatric kidney tumor, is genetically heterogeneous. Wilms tumor is associated with mutations of WT1, a zinc-finger transcription factor that is essential for the development of the metanephric kidney and the urogenital system. The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma. WT1 protein has been identified in proliferative mesothelial cells, malignant mesothelioma, ovarian carcinoma, gonadoblastoma, nephroblastoma and desmoplastic small round cell tumor. WT1 protein expression in mesothelial cells has become a reliable marker for the diagnosis of mesotheliomas.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.